Aim To evaluate the efficacy and toxicity of paclitaxel and cisplatin plus CF/fluorouracil regimen treatment in the advanced esophageal cancer . Methods 55 patients of advanced esophageal cancer were treated. The treatment schedule consisted of paclitaxel iv 135 ～175 mg ·m -2 ,dl , and cisplatin 20 mg · m -2 ,iv,dl ～ d4 plus CF 0. 2 g · m -2 ,iv ,d2 ～ d3 .and fluorouracil 2 g · m -2 ,civ for 46 h , d2 ～ d3 were administered every three weeks. Results All 55 patients were eligible for clinical response evaluation. The overall response rate was 56. 3％ ,including 2 cases of CR,29 cases of PR ,15 cases of SD and 9 cases of PD respectively. The major side-effects were neutropenia, gastrointestinal reaction ,oral mucositis , peripheral neurotoxicity. Conclusion Paclitaxel and cisplatin plus CF / fluorouracil regimen has a palliative role in patients with a dvanced esophageal cancer.%目的 观察紫杉醇联合顺铂(DDP)加亚叶酸钙(CF)和5-氟尿嘧啶(5-FU)方案治疗晚期食管癌的近期疗效及安全性.方法 观察55例晚期食管癌患者,PTX 135～175 mg·m-2,静脉滴注3 h,d1,DDP 20 mg·m-2 d1～d4、CF 0.2g·m-2 d2～d3、5-FU 2.0g·m-2持续静滴46 h(d2～d3),3周一疗程,至少进行2个周期后评价.结果 55例患者中可评价疗效的患者55例,其中CR 2例,占3.6%;PR 29例,占52.7%;有效率(CR+PR)为56.3%;SD 15例,占27.3%;PD 9例,占16.4%.临床毒副反应为骨髓抑制,消化道反应,口腔黏膜炎,周围神经毒性.结论 紫杉醇联合顺铂、5-氟尿嘧啶方案对晚期食管癌疗效肯定,毒副反应轻,值得临床推广应用.
展开▼
